ClinicalTrials.gg
Drug

Cytarabine clinical trials

Also written Ara-C, Cytosar-U, DepoCyt and CHX-3311.

Includes 19 studies of Liposomal Cytarabine.

studies test it
497
open now
76
in phase 3
81
first study started
1990
Related medicines add 1 study

Counted the way a researcher would: Cytarabine with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.

This browser remembers your choice.

How each study uses Cytarabine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Cytarabine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
17 Jun 1969 · CYTARABINE · NDA 016793 (FDA, Drugs@FDA)
European Union
11 Jul 2001 · DepoCyte · EMEA/H/C/000317 (EMA; as Liposomal Cytarabine; now withdrawn)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Cytarabine
377
cytosine arabinoside
81
arabinosylcytosine
44
Cytosar
39
arabinofuranosylcytosine
37

Brand

Cytosar-U
75
DepoCyt
31

Development codes

CHX-3311
3
NSC-63878
3
U-19920
2
U-19920A
1

Other names

Ara-C
139
Aracytine
2
Aracytin
1

In one entry with another drug

Given together, or one or the other

CACAG+VEN
4
Methotrexate/hydrocortisone/cytarabine
3
Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor
3
Safety
3
DHAP
2

Studies by the year they started

493 studies that test it; most in 2016 (28); 2 more planned to start later

Studies that test Cytarabine, by start year
YearStudies
19901
19921
19933
19944
19956
19966
19974
19989
199913
200018
200116
200214
200322
200419
200517
200615
200724
200815
200918
201023
201114
201219
201317
201413
201514
201628
201714
201827
201911
20208
20217
202213
202313
202420
202516
202611

Who runs them

Industry 32 · Other 465

M.D. Anderson Cancer Center (46) · National Cancer Institute (NCI) (37) · Children's Oncology Group (21) · St. Jude Children's Research Hospital (17) · Fred Hutchinson Cancer Center (16) · Institute of Hematology & Blood Diseases Hospital, China (13) · Memorial Sloan Kettering Cancer Center (11) · University of Washington (10)

Often tested with

Tested in the same studies.

Etoposide (102) · Cyclophosphamide (88) · Methotrexate (82) · Daunorubicin (75) · Vincristine (63) · Dexamethasone (61) · Idarubicin (59) · Mitoxantrone (48)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 10 phase 3 studies under way

Cytarabine is the comparator. A study of two new drugs counts under both.

  • 2CPX-351 · University of Birmingham, University of Ulm · next primary completion Jun 2027
  • 2Azacitidine · Institute of Hematology & Blood Diseases Hospital, China, The First Affiliated Hospital of Soochow University · next primary completion Dec 2026
  • 2Venetoclax · Institute of Hematology & Blood Diseases Hospital, China, The First Affiliated Hospital of Soochow University · next primary completion Dec 2026
  • 1Odronextamab · Regeneron Pharmaceuticals · next primary completion May 2028
  • 1Fludarabine · University of Birmingham
  • 1Busulfan · University of Birmingham
  • 1Thiotepa · University of Birmingham
  • 1Galinpepimut-s · Sellas Life Sciences Group
Reaching primary completion within a year · 24, 6 in phase 3

Studies that test Cytarabine, phase 3 first.

Studies

Open first, then newest update. How each study uses Cytarabine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 497

See all 497 studies that test Cytarabine →

Given beside what is tested · 484 — Cytarabine is usual care or a partner of the new treatment

Showing 20 of 484.

As the comparator · 40 — what is tested is compared with Cytarabine

Showing 20 of 40.

Codes

What other systems call Cytarabine · ClinicalTrials.gg INT007290

  • MeSH (NLM) D003561CytarabineConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 04079A1RDZCYTARABINEConfirmed FDA, NLM, Wikidata
  • RxNorm 3041Confirmed FDA, Wikidata
  • Wikidata Q180983cytarabineConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C408CytarabineOne source FDA
  • DrugBank DB00987One source Wikidata

Also registered as cytarabine hydrochloride (UNII 33K3DB6591).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.